Theratechnologies Inc. (NASDAQ:THTX) Short Interest Up 2,740.1% in March

Theratechnologies Inc. (NASDAQ:THTX - Get Free Report) saw a significant growth in short interest in March. As of March 31st, there was short interest totalling 1,190,000 shares, a growth of 2,740.1% from the March 15th total of 41,900 shares. Based on an average daily trading volume, of 1,030,000 shares, the short-interest ratio is currently 1.2 days. Currently, 6.2% of the shares of the company are short sold.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Raymond James Financial Inc. acquired a new position in shares of Theratechnologies during the fourth quarter valued at approximately $27,000. Bank of America Corp DE raised its stake in Theratechnologies by 1,416.7% in the 4th quarter. Bank of America Corp DE now owns 16,487 shares of the company's stock valued at $30,000 after purchasing an additional 15,400 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in Theratechnologies during the 4th quarter worth $33,000. BNP Paribas Financial Markets purchased a new stake in shares of Theratechnologies during the fourth quarter worth $36,000. Finally, Virtu Financial LLC acquired a new stake in shares of Theratechnologies in the fourth quarter valued at about $40,000.

Theratechnologies Trading Down 1.9 %

NASDAQ:THTX traded down $0.05 during trading hours on Friday, reaching $2.52. 758,784 shares of the company were exchanged, compared to its average volume of 770,955. The stock's 50-day moving average is $1.71 and its 200-day moving average is $1.56. Theratechnologies has a twelve month low of $1.08 and a twelve month high of $3.13. The firm has a market cap of $115.87 million, a PE ratio of -25.20 and a beta of 1.11.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Jones Trading upgraded Theratechnologies from a "hold" rating to a "strong-buy" rating in a research report on Friday, April 11th. Research Capitl raised Theratechnologies to a "strong-buy" rating in a report on Friday, February 14th.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.